FDA warns of cold remedy dangers

Article Abstract:

The US FDA has called on pharmaceutical companies not to use an ingredient that is linked to increased risk of strokes. The ingredient, phenylpropanolamine (PPA), is found in over-the-counter cold remedies and appetite suppressants. The FDA is implementing a rule, which in effect, will ban the use of PPA in non-presceiption remedies. The agency has decided not to pull PPA products from store shelves since they do not fall under the immediate-hazard category. Instead, it has issued a public health warning to alert consumers of the potential risk.

Proprietary Cold Preps

---

RU-486 certification for doctors could lessen pill's use

Article Abstract:

A survey conducted by the Population Council showed that the use of 'abortion pill' RU-486 may be limited severely if the FDA requires doctors to be certified before prescribing the drug. RU-486 or mifepristone has been used by more than 500,000 women in Western Europe but has yet to be approved by the FDA for use in the US. The drug's major advantage is that would attract physicians who are reluctant to perform surgical abortions for fear of incurring the ire of abortion opponents.

Regulation of Agricultural Marketing and Commodities, Food & Drug Administration, Fertility Preparations, Fertility agents

---

FDA prescribes Prozac to treat severe PMS

Article Abstract:

Prozac, a treatment for depression, has been approved by the FDA for severe premenstrual syndrome (PMS) on Jul 6, 2000. The drug will be introduced in the market next month by Eli Lilly and Co under the name Sarafem for the treatment of premenstrual dysphoric disorder. It will be sold in blister packs of 28 and is expected to have big market since 85% of menstruating women report having at least one PMS symptom.

Antidepressant Preparations, Eli Lilly and Co., Antidepressants

Similar abstracts:

• Abstracts: Compaq warns of loss for third quarter. Sales predictions sock PC stocks. Market smiles on H-P's first quarter
• Abstracts: Bright lights, big controversy. Further scrutiny puts Ford in the hot seat. Safety group to rate autos on rollover risk
• Abstracts: Defense contractors' deal stumbles. Final OK expected this week for AOL merger. France Telecom to buy cellphone firm
• Abstracts: Housing market cools. Shoppers appear to have checked out. Initial public offering dazzles
• Abstracts: Daimler questions crash tests. Firestone recall shifts into higher gear

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.